Ascletis is an innovative R&D driven biotech with two commercial products and listed on Hong Kong Stock Exchange (Ascletis, 1672.HK). Ascletis’ mission is to address unmet medical needs in three therapeutic areas: viral, cancer and fatty liver diseases. Led by a management team with deep expertise and a proven track record, Ascletis has developed a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization.
ASC22，PD-L1 antibody for HBV, first-in-class, subcutaneous, room temperature stable，phase 2 ready.
ASC40, first-in-class FASN inhibitor for NASH, phase 2 ready. ASC09, best-in-class HIV protease inhibitor with unprecedented genetic barrier, phase 2.
ASC06, first systematically delivered, dual-targeting siRNA for liver cancer, phase 1.
Ascletis Appoints Former MSD Global Vice President Dr. Zhengqing Li as Chief Medical ......
Ascletis and 3-V Biosciences Announce NASH Strategic License and Series E Financing......
Dr. Jinzi J. Wu to Speak at the 19th Annual Conference of China Entrepreneurs Forum......
Our greatest assets are our employees. Ascletis is an equal opportunity employer and focused on providing a positive work environment where courageous innovation is encouraged and expected.
Our mission is to become a world-class biotechnology company addressing unmet medical needs in three therapeutic areas: anti-viral, cancer and fatty liver disease, for the patients in China and worldwide. Our highly talented team of researchers and professionals who passionately share in this common mission.
We offer competitive salaries and benefits that reward employees for their contribution to the company. If you’re interested in learning more about what we have to offer, please email your CV to email@example.com. We will look to match any current and upcoming openings to your area of expertise.